severe or persistent upper abdominal pain should prompt urgent medical assessment [10] [11] Dehydration and acute kidney injury (AKI): gastrointestinal fluid losses can lead to dehydration, which may precipitate AKI, particularly in those with pre-existing renal impairment or those taking nephrotoxic medicines Delayed gastric emptying: this may affect the absorption of orally administered medicines, including contraceptive pills and thyroid replacement therapy [11] Injection site reactions: redness, bruising, or discomfort at the subcutaneous injection site Heart rate changes: increases in resting heart rate have been noted with GLP-1 class agents [14] [15] Hypoglycaemia: particularly if used alongside insulin or sulphonylureas Potential pancreatitis risk: a class concern with GLP-1 receptor agonists
References Vukojevic J, Milavi M, Perovi D, Ili S, ili AZ, uran N, trbe S, Zorii Z, Filipi I, Brei P, Seiverth S, Sikiri P
A.RuttenM
El liofilizado se mantiene a 20C
In the meantime, the regulator has agreed to not take action against compounders of tirzepatide until December 19, unless the agency makes an earlier decision on remand, according to a Leerink investor note issued last month
10.25046/aj020390 32 De VisserK
